Staging of α-synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved

• Published in: Movement disorders Vol. 25; no. 11; pp. 1701 - 1707
• Main Authors: Ubeda-Bañon, Isabel, Saiz-Sanchez, Daniel, de la Rosa-Prieto, Carlos, Mohedano-Moriano, Alicia, Fradejas, Noelia, Calvo, Soledad, Argandoña-Palacios, Lucia, Garcia-Muñozguren, Susana, Martinez-Marcos, Alino
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15-08-2010; Wiley
• Subjects: alpha-Synuclein - genetics; alpha-Synuclein - metabolism; Animals; Biological and medical sciences; calcium binding protein; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Disease Models, Animal; Gene Expression Regulation - genetics; Humans; Medical sciences; Mice; Mice, Transgenic; Mutation - genetics; Neurology; Neurons - classification; Neurons - metabolism; olfactory bulb; Olfactory Bulb - metabolism; Olfactory Bulb - pathology; olfactory deficit; Parkinson Disease - genetics; Parkinson Disease - pathology; Parkinson's disease; Parvalbumins - metabolism; transgenic mice; Tyrosine 3-Monooxygenase - metabolism; tyrosine hydroxylase; Ubiquitins - metabolism; α-Synuclein; α-Synuclein; Nervous system diseases; Parkinson's disease; Central nervous system; Parkinson disease; Encephalon; Cerebral disorder; calcium binding protein; tyrosine hydroxylase; Olfactory pathway; olfactory deficit; transgenic mice; Central nervous system disease; Olfactory bulb; Degenerative disease; Models; Extrapyramidal syndrome
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.23197

Impaired olfaction is an early symptom of Parkinson's disease. The underlying neuropathology likely includes α‐synucleinopathy in the olfactory bulb at an earlier stage (Braak's stage1) than pathology in the substantia nigra, which is not observed until stage 3. In this report, we investigated the distribution and cell types affected by α‐synuclein in the olfactory bulb of transgenic mice (2–8 months of age) expressing the human A53T variant of α‐synuclein. α‐Synuclein immunostaining progressively affects interneurons and mitral cells. Double labeling studies demonstrate that dopaminergic cells are hardly involved, whereas glutamatergic‐ and calcium binding protein‐positive cells are severely affected. This temporal evolution and the cell types expressing α‐synuclein are reminiscent of idiopathic Parkinson's disease and support the usefulness of this model to address specific topics in the premotor phase of the disease. © 2010 Movement Disorder Society